Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trametinib + anlotinib + tislelizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy of three anticancer agents: **trametinib**, a selective MEK1/2 inhibitor that blocks the MEK/ERK signaling pathway downstream of RAS/RAF and is approved for use in cancers with BRAF mutations; **anlotinib**, a small molecule multi-targeted receptor tyrosine kinase inhibitor that targets VEGFR, FGFR, PDGFR, and c-Kit, thereby inhibiting tumor angiogenesis and proliferation; and **tislelizumab**, a humanized monoclonal antibody targeting the immune checkpoint PD-1, designed to enhance antitumor immune responses by preventing PD-1-mediated T-cell inhibition. This triple combination is under clinical investigation, particularly in non-small cell lung cancer (NSCLC) with KRAS or BRAF mutations, and other solid tumors, aiming to synergistically inhibit cancer growth through blockade of oncogenic signaling, angiogenesis, and immune evasion pathways[1][2][5][7].
- Other names
- trametinib + anlotinib + tislelizumab
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR4 (Vascular endothelial growth factor Receptor-3)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)FGFR1 (Fibroblast growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on trametinib + anlotinib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trametinib + anlotinib + tislelizumab.